



**Ruediger B Mueller**

**Kontakt**

Ruediger B Mueller

## Publikationen (10)

Riek M, Scherer A, Möller B, Ciurea A, Von Mühlennen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. *Sci Rep* 2023; 13:17776.

Mueller R, Schulze-Koops H, Furst D, Cohen S, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). *Clin Rheumatol* 2022; 41:1045-1055.

Thalmann R, von Kempis J, Zraggen A, Schiff M, Sokka T, Dietrich T, Schulze-Koops H, Mueller R. Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes. *Clin Exp Rheumatol* 2021

Mueller R, Schulze-Koops H, Rubbert-Roth A, Hasler P, Souza A, Durmisi M, Mattow F, Popp F, Hasler C, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. *J Clin Med* 2019; 8

von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger P, Vallelian F, Schaer D, Mueller R. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. *Swiss Med Wkly* 2019; 149:w20022.

von Kempis J, Deutsche S, Reschling N, Villiger R, Villiger P, Vallelian F, Scher D, Mueller R. 51-year-old man with acute coronary syndrome and bipulmonary infiltrates. *Swiss Medical Weekly* 2019; 2019;149:w20022

Mueller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. *J Clin Med* 2019; 8

Pirker I, Krane-Nuber J, Albrich W, Mueller R, Neumann T. Atypical presentation of *Pneumocystis jirovecii* pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation. *BMC Rheumatology* 2018; 2

Mueller R, Kaegi T, Haile S, Schulze-Koops H, Schiff M, von Kempis J. Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. *RMD Open* 2018; 4:e000673.

Popp F, Semela D, von Kempis J, Mueller R. Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept. *BMJ Case Rep* 2018; 2018

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)